<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702492</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-9274-901</org_study_id>
    <nct_id>NCT02702492</nct_id>
  </id_info>
  <brief_title>PAK4 and NAMPT in Participants With Solid Malignancies or NHL (PANAMA)</brief_title>
  <acronym>PANAMA</acronym>
  <official_title>A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the
      treatment of participants with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, multi-center, open-label clinical study with separate Dose
      Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of
      KPT-9274, a dual inhibitor of PAK4 and NAMPT, in participants with advanced solid
      malignancies (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard
      therapeutic options considered useful by the investigator have been exhausted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) for KPT-9274 administered alone and with co-administration of niacin ER (extended release) (vitamin B3/nicotinic acid)</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Parts A &amp; B: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) for KPT-9274 co-administered with nivolumab</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Part C: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤ 1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>NHL</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>KPT-9274</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[CLOSED TO ENROLLMENT]
Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPT-9274 &amp; Niacin Extended Release (ER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[CLOSED TO ENROLLMENT]
500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPT-9274 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C:
Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.
Nivolumab 480 mg IV administered Day 1 during each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPT-9274</intervention_name>
    <arm_group_label>KPT-9274</arm_group_label>
    <arm_group_label>KPT-9274 &amp; Niacin Extended Release (ER)</arm_group_label>
    <arm_group_label>KPT-9274 + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin ER</intervention_name>
    <arm_group_label>KPT-9274 &amp; Niacin Extended Release (ER)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>KPT-9274 + Nivolumab</arm_group_label>
    <other_name>Opdivo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following inclusion criteria to be eligible to enroll in
        the Part C of this study.

          1. Should have unresectable advanced, recurrent or metastatic melanoma and must have
             objective and measurable melanoma by RECIST 1.1 after disease progression on a prior
             anti-PD-1 or anti-PD-L1 therapy.

          2. ECOG performance status of ≤ 2.

          3. Life expectancy of ≥ 3 months.

          4. Adequate hepatic function:

               -  Total bilirubin &lt; 1.5 times the ULN (except participants with Gilbert's syndrome
                  [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3
                  times ULN),

               -  AST and ALT ≤ 2.5 times ULN (except participants with known liver involvement of
                  their advanced solid malignancy who must have an AST and ALT ≤ 5.0 times ULN).

          5. Adequate renal function:

               -  Estimated creatinine clearance of ≥ 60 mL/min, calculated using the formula of
                  Cockroft and Gault (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if
                  female.

          6. Adequate hematopoietic function:

               -  Total WBC count ≥ 1500/mm³, ANC ≥ 1000/mm³, Hb ≥ 10.0 g/dL, platelet count ≥
                  100,000/mm³

        Exclusion Criteria:

        Participants meeting any of the following exclusion criteria are not eligible to enroll in
        this study.

          1. ≤ 2 weeks since the last prior therapeutic regimen for melanoma. Palliative steroids
             for disease related symptoms &lt; 7 days prior to C1D1, unless physiologic doses of
             steroids are used.

          2. Have not recovered or stabilized (Gr 1 or to their baseline for non-hematologic
             toxicities, ≤ Gr 2 or to their baseline for hematologic toxicities) from toxicities
             related to their previous treatment except for alopecia. In specific cases,
             participants with Gr 2 non-hematologic toxicities will be allowed following approval
             by the Karyopharm medical monitor.

          3. Untreated CNS disease or leptomeningeal involvement are excluded. Participants without
             active brain or leptomeningeal metastases after prior treatment with local therapies
             are eligible provided that the treatment had been done ≥ 2 weeks prior to enrollment.

          4. Active infection with completion of therapeutic antibiotics, antivirals, or
             antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or
             antifungals are permitted.

          5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting
             or diarrhea that could interfere with the absorption of KPT-9274.

          6. Active peptic ulcer disease or other active gastrointestinal bleeds.

          7. Requiring treatment with corticosteroids at doses higher than substitute therapy (&gt; 10
             mg prednisone), are unstable with substitute hormonal therapy, or are deemed to be
             likely to re-occur by the treating physician when administered nivolumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jatin Shah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jatin Shah, MD</last_name>
    <email>jshah@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoni Ribas, MD</last_name>
      <email>aribas@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Antoni Ribas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University, Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>NYU-Laura &amp; Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Cho</last_name>
      <phone>212-731-5871</phone>
      <email>daniel.cho@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Berlin, MD</last_name>
    </contact>
    <contact_backup>
      <email>jordan.berlin@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jordan Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aung Naing</last_name>
      <phone>713-563-0803</phone>
      <email>anaing@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Aung Naing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albiruni Razak, MB, BCh</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>3883</phone_ext>
      <email>Albiruni.razak@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Albiruni Razak, MB, Bch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAK4</keyword>
  <keyword>KPT-9274</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>NHL</keyword>
  <keyword>solid tumors</keyword>
  <keyword>NAMPT</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

